$BCAB News

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BioAtla shares are trading lower after the company announced a 1-for-50 reverse stock split. Also, the company reported Q4 financial results.

BioAtla Announces Share Consolidation

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate

BioAtla shares are trading lower after the company announced a 50-for-1 share consolidation.

BioAtla Announces 50-For-1 Share Consolidation, Effective April 6

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

BioAtla Initiates Exploration Of Strategic Initiatives Including Workforce Reduction Of ~70%; Appoints Chris Vasquez CFO, Succeeding Richard Waldron

BioAtla Board Initiates Formal Process To Explore And Evaluate Strategic Options To Monetize Assets

BioAtla Files For Mixed Shelf Offering Of Up To $200M

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla And GATC Health Announce $40M Special Purpose Vehicle Transaction, With $5M Initial Closing And Remaining $35M Expected In Q1 2026, To Fund Phase 3 Ozuriftamab Vedotin Registrational Trial In 2L+ OPSCC

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

BioAtla Secures $7.5M Advance And Up To $15M Standby Equity Commitment To Support Strategic Transaction

BioAtla (BCAB) Q3 2025 Earnings Call Transcript

BioAtla, Inc. 2025 Q3 - Results - Earnings Call Presentation